The estimated Net Worth of Alisa Lask is at least $471 dollars as of 11 September 2019. Mrs. Lask owns over 250 units of Nephros Inc stock worth over $471 and over the last 5 years she sold NEPH stock worth over $0. In addition, she makes $0 as Director at Nephros Inc.
Alisa has made over 1 trades of the Nephros Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she bought 250 units of NEPH stock worth $1,613 on 11 September 2019.
The largest trade she's ever made was buying 250 units of Nephros Inc stock on 11 September 2019 worth over $1,613. On average, Alisa trades about 36 units every 0 days since 2019. As of 11 September 2019 she still owns at least 250 units of Nephros Inc stock.
You can see the complete history of Mrs. Lask stock trades at the bottom of the page.
Alisa Lask is Director of the company. Ms. Lask is currently Vice President & General Manager at Galderma, a Nestle Skin Health company. She oversees the franchise of pharmaceutical, medical device injectable brands, and cosmeceutical skincare products. Previously, Mrs. Lask was Senior Director of Global Strategic Marketing at Allergan, Vice President, Global Strategic Marketing at Zimmer Biomet, and spent 10 years at Eli Lilly in a number of positions of increasing responsibility, with her final role as Director, Global Neuroscience. Ms. Lask received her M.B.A. from the University of Michigan in Marketing and her B.A. in Marketing and Finance from Miami University of Ohio.
Alisa's mailing address filed with the SEC is C/O NEPHROS, INC., 380 LACKAWANNA PLACE, SOUTH ORANGE, NJ, 07079.
Over the last 6 years, insiders at Nephros Inc have traded over $0 worth of Nephros Inc stock and bought 188,822 units worth $443,998 . The most active insiders traders include Capital Lp Wexford Gp Llcda..., Robert R. Jr. Banks y Andrew Astor. On average, Nephros Inc executives and independent directors trade stock every 70 days with the average trade being worth of $15,834. The most recent stock trade was executed by Arthur H Amron on 28 May 2024, trading 5,000 units of NEPH stock currently worth $11,200.
nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters. nephros filters capture contaminants as small as 5 nanometers in size; they minimize exposure to a wide variety of bacteria, viruses, fungi, parasites, and endotoxins. nephros filters use a proprietary hollow fiber technology; the hollow fiber design enables the filters to optimize the three elements critical to filter performance: • filtration – as low as 5 nanometers • flow rate – minimal disruption • filter life – up to 12 months nephros was founded in 1997, by healthcare professionals affiliated with columbia university medical center, initially to address the needs of chronic renal failure patients. the company has developed an alternative to current hemodialysis therapy known as mid-dilution hemodiafiltration (mid-hdf). nephros’ proprietary blood purification technologies enable mid-hdf to be offered to chronic renal failure patients. nephros mid-dilution fil
Nephros Inc executives and other stock owners filed with the SEC include: